Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Revenue
Expenses:
Research and development	93,270		130,180
Selling, general and administrative	83,605	43,098	204,447	165,264
Share-based Payment Arrangement, Expense	120,098		120,098
Total expenses	296,973	43,098	454,725	165,264
Loss from operations	(296,973)	(43,098)	(454,725)	(165,264)
Other income (expense)
Interest income (expense)		281	96	281
Net loss	$ (296,973)	$ (42,817)	$ (454,629)	$ (164,983)
Net loss per share - basic and diluted (in dollars per share)	$ 0	$ 0	$ (0.01)	$ 0
Weighted average number of common shares outstanding – basic and diluted (in shares)	86,522,569	67,022,568	78,165,426	53,665,425